Literature DB >> 9436664

Influence of gonadotrophin-releasing hormone agonist total dose in the ovarian stimulation in the long down-regulation protocol for in-vitro fertilization.

C Alvarez1, N Cremades, N Blasco, R Bernabeu.   

Abstract

The goal of our study was to assess whether the total dose of gonadotrophin-releasing hormone agonist (GnRHa) administered affects the success of an in-vitro fertilization (IVF) programme. A retrospective analysis was performed on a total of 72 IVF cycles carried out on 70 patients with different causes of infertility included in our assisted reproduction programme. Cycles were divided into two groups according to the number of days of GnRHa administration (leuprolide acetate 1 mg/day) necessary until ovarian desensitization occurred: group I (GI) < 13 days (n = 27) and group II (GII) > or = 13 days (n = 45). The following parameters were assessed: number of gonadotrophin ampoules, number of stimulation days, endometrial thickness on the day of human chorionic gonadotrophin (HCG) administration, number of recovered oocytes, pregnancy rate. Pregnancy rate/cycle and pregnancy rate/transfer were positively correlated with the dose of GnRHa (GI: 44 and 60% respectively versus GII: 20% and 25% respectively). It is concluded that a long administration of GnRHa has no effect upon ovarian response, although the pregnancy rate is subsequently decreased.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9436664     DOI: 10.1093/humrep/12.11.2366

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  2 in total

1.  Comparison between a single dose of goserelin (depot) and multiple daily doses of leuprolide acetate for pituitary suppression in IVF treatment: a clinical endocrinological study of the ovarian response.

Authors:  Selmo Geber; Liana Sales; Marcos A C Sampaio
Journal:  J Assist Reprod Genet       Date:  2002-07       Impact factor: 3.412

2.  Low dose gonadotropin-releasing hormone agonist treatments with early discontinuation for controlled ovarian hyperstimulation in an in vitro fertilization program.

Authors:  Su-Long Lee; Jinu-Hwang Su; Katsuo Ikuta; Kaoru Suzumori
Journal:  Reprod Med Biol       Date:  2003-03-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.